Global Blood Therapeutics Inc (GBT) Expected to Post Earnings of -$0.69 Per Share

Brokerages forecast that Global Blood Therapeutics Inc (NASDAQ:GBT) will post earnings per share of ($0.69) for the current quarter, according to Zacks. Zero analysts have issued estimates for Global Blood Therapeutics’ earnings. The highest EPS estimate is ($0.52) and the lowest is ($0.82). Global Blood Therapeutics posted earnings per share of ($0.56) during the same quarter last year, which indicates a negative year over year growth rate of 23.2%. The company is expected to report its next earnings report on Thursday, May 11th.

According to Zacks, analysts expect that Global Blood Therapeutics will report full year earnings of ($2.83) per share for the current financial year, with EPS estimates ranging from ($3.50) to ($2.23). For the next fiscal year, analysts expect that the firm will post earnings of ($3.01) per share, with EPS estimates ranging from ($3.62) to ($2.38). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that follow Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Monday, March 13th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.10. During the same quarter in the previous year, the business posted ($0.53) earnings per share.

Several research analysts have issued reports on the company. Cantor Fitzgerald assumed coverage on Global Blood Therapeutics in a report on Wednesday, March 15th. They issued an “overweight” rating and a $61.00 price target on the stock. Zacks Investment Research cut Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, March 16th. Roth Capital set a $47.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a report on Monday, March 20th. Wedbush reissued an “outperform” rating and set a $73.00 target price on shares of Global Blood Therapeutics in a research note on Monday, March 20th. Finally, JPMorgan Chase & Co. reissued a “buy” rating and set a $44.00 target price on shares of Global Blood Therapeutics in a research note on Wednesday, March 15th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Global Blood Therapeutics currently has a consensus rating of “Buy” and an average target price of $51.23.

In other Global Blood Therapeutics news, major shareholder Robert I. Tepper sold 31,225 shares of the business’s stock in a transaction on Thursday, April 6th. The shares were sold at an average price of $33.23, for a total transaction of $1,037,606.75. Following the sale, the insider now directly owns 229,773 shares of the company’s stock, valued at approximately $7,635,356.79. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.10% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the stock. TLP Group LLC bought a new position in Global Blood Therapeutics during the third quarter valued at approximately $111,000. Daiwa SB Investments Ltd. bought a new position in Global Blood Therapeutics during the first quarter valued at approximately $120,000. Bessemer Group Inc. bought a new position in Global Blood Therapeutics during the fourth quarter valued at approximately $335,000. Teachers Advisors LLC boosted its position in Global Blood Therapeutics by 19.3% in the fourth quarter. Teachers Advisors LLC now owns 29,682 shares of the company’s stock valued at $429,000 after buying an additional 4,812 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in Global Blood Therapeutics by 53.3% in the third quarter. Wells Fargo & Company MN now owns 20,744 shares of the company’s stock valued at $478,000 after buying an additional 7,212 shares in the last quarter. Institutional investors and hedge funds own 56.36% of the company’s stock.

Shares of Global Blood Therapeutics (NASDAQ:GBT) traded down 3.82% on Friday, reaching $30.25. The company had a trading volume of 784,372 shares. The company has a 50 day moving average price of $33.76 and a 200 day moving average price of $22.00. The stock’s market capitalization is $1.32 billion. Global Blood Therapeutics has a 52-week low of $13.35 and a 52-week high of $41.15.

ILLEGAL ACTIVITY WARNING: “Global Blood Therapeutics Inc (GBT) Expected to Post Earnings of -$0.69 Per Share” was originally published by sleekmoney and is owned by of sleekmoney. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at http://sleekmoney.com/global-blood-therapeutics-inc-gbt-expected-to-post-earnings-of-0-69-per-share/1737739.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

5 Day Chart for NASDAQ:GBT

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/global-blood-therapeutics-inc-gbt-expected-to-post-earnings-of-0-69-per-share/1737739.html

Receive News & Ratings for Global Blood Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *